Details of the Drug

General Information of Drug (ID: DMHZJCG)

Drug Name
Pentamidine
Synonyms
Lomidine; Nebupent; PENTAM; PNT; Pentacarinat; Pentamide; Pentamidin; Pentamidina; Pentamidinum; Pneumopent; PENTAMIDINE ISETHIONATE; Pentamidina [DCIT]; Pentamidine isetionate; Pentamidine mesylate; MB 800; Pentam 300; Lomidine (TN); MB-800; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamidine (INN); Pentamidinum [INN-Latin]; RP-2512; Nebupent (*Isethionate); Pentacarinat (*Isethionate); Pentam 300 (*Isethionate); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid;Pentamidine [INN:BAN:DCF]; RP 2512 (*Isethionate); P,p'-(Pentamethylenedioxy)bis[benzamidine]; P,p'-(Pentamethylenedioxy)dibenzamidine; P,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-(9CI); 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; 4, 4'-Diamidinodiphenoxypentane; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(Pentamethylenedioxy)dibenzamide; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; 4,4'-Diamidinodiphenoxypentane; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
Indication
Disease Entry ICD 11 Status REF
African trypanosomiasis 1F51 Approved [1]
Fungal infection 1F29-1F2F Approved [2]
Pneumocystis pneumonia CA40.20 Approved [1]
Human immunodeficiency virus infection 1C62 Withdrawn from market [3]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 340.4
Logarithm of the Partition Coefficient (xlogp) 2.6
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption
The drug is poorly absorbed from the gastrointestinal tract []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 74 mL/min/kg [5]
Elimination
12% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 9.1 - 13.2 hours [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.74989 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.09% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 53 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 100 mg/mL [4]
Chemical Identifiers
Formula
C19H24N4O2
IUPAC Name
4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
Canonical SMILES
C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N
InChI
InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
InChIKey
XDRYMKDFEDOLFX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4735
ChEBI ID
CHEBI:45081
CAS Number
100-33-4
DrugBank ID
DB00738
TTD ID
D05EAM
VARIDT ID
DR00085
INTEDE ID
DR1252
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tryptase alpha/beta-1 (Tryptase) TTM1TDX TRYB1_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [9]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alpha-1-antichymotrypsin (SERPINA3) OT9BP2S0 AACT_HUMAN Gene/Protein Processing [11]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Gene/Protein Processing [11]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [12]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [13]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Gene/Protein Processing [14]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Gene/Protein Processing [14]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Gene/Protein Processing [14]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [14]
Double-strand break repair protein MRE11 (MRE11) OTGU8TZM MRE11_HUMAN Gene/Protein Processing [15]
Fatty acid-binding protein, liver (FABP1) OTR34ETM FABPL_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease African trypanosomiasis
ICD Disease Classification 1F51
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tryptase alpha/beta-1 (Tryptase) DTT TPSAB1 3.09E-07 1.07 0.89
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 8.27E-06 1.93E-01 5.03E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.93E-03 -2.19E-01 -4.49E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.57E-07 -1.95E-01 -4.24E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.85E-05 8.08E-01 6.07E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.65E-02 -4.37E-02 -7.84E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 1.21E-04 -2.33E-01 -5.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.90E-01 2.35E-02 7.88E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Pentamidine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Ketoconazole. Fungal infection [1F29-1F2F] [16]
Coadministration of a Drug Treating the Disease Different from Pentamidine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Pentamidine and Ivosidenib. Acute myeloid leukaemia [2A60] [17]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Midostaurin. Acute myeloid leukaemia [2A60] [16]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Idarubicin. Acute myeloid leukaemia [2A60] [16]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Arn-509. Acute myeloid leukaemia [2A60] [18]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Gilteritinib. Acute myeloid leukaemia [2A60] [19]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Oliceridine. Acute pain [MG31] [16]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Rivastigmine. Alzheimer disease [8A20] [16]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Donepezil. Alzheimer disease [8A20] [16]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Pentamidine and Metronidazole. Amoebiasis [1A36] [20]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Pentamidine and Ivabradine. Angina pectoris [BA40] [18]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Pentamidine and Bepridil. Angina pectoris [BA40] [16]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Pentamidine and Dronedarone. Angina pectoris [BA40] [16]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Pentamidine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [21]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Cilostazol. Arterial occlusive disease [BD40] [16]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Posaconazole. Aspergillosis [1F20] [16]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Levalbuterol. Asthma [CA23] [22]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Terbutaline. Asthma [CA23] [23]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Pirbuterol. Asthma [CA23] [23]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Salbutamol. Asthma [CA23] [22]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Formoterol. Asthma [CA23] [23]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Desipramine. Attention deficit hyperactivity disorder [6A05] [16]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Ofloxacin. Bacterial infection [1A00-1C4Z] [24]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Clarithromycin. Bacterial infection [1A00-1C4Z] [16]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Pentamidine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [16]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Pentamidine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [24]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [24]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Norfloxacin. Bacterial infection [1A00-1C4Z] [24]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Pentamidine and Rabeprazole. Bacterial infection [1A00-1C4Z] [25]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Levofloxacin. Bacterial infection [1A00-1C4Z] [24]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [16]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Telithromycin. Bacterial infection [1A00-1C4Z] [16]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Retigabine. Behcet disease [4A62] [16]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Etidronic acid. Bone paget disease [FB85] [26]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Loperamide. Bowel habit change [ME05] [27]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Eribulin. Breast cancer [2C60-2C6Y] [16]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lapatinib. Breast cancer [2C60-2C6Y] [16]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Bosutinib. Breast cancer [2C60-2C6Y] [18]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Pentamidine and Iodipamide. Cholelithiasis [DC11] [28]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [29]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [23]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [22]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [23]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [23]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [23]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Isoproterenol. Conduction disorder [BC63] [22]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Halothane. Corneal disease [9A76-9A78] [16]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Propofol. Corneal disease [9A76-9A78] [30]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Sevoflurane. Corneal disease [9A76-9A78] [16]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Methoxyflurane. Corneal disease [9A76-9A78] [18]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Probucol. Coronary atherosclerosis [BA80] [16]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Clofazimine. Crohn disease [DD70] [31]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Pentamidine and Mifepristone. Cushing syndrome [5A70] [16]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Pentamidine and Pasireotide. Cushing syndrome [5A70] [16]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Osilodrostat. Cushing syndrome [5A70] [18]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Sertraline. Depression [6A70-6A7Z] [16]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Pentamidine and Escitalopram. Depression [6A70-6A7Z] [16]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Clomipramine. Depression [6A70-6A7Z] [16]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Doxepin. Depression [6A70-6A7Z] [16]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Maprotiline. Depression [6A70-6A7Z] [16]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [16]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Deutetrabenazine. Dystonic disorder [8A02] [32]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Ingrezza. Dystonic disorder [8A02] [33]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Solifenacin. Functional bladder disorder [GC50] [16]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Pentamidine and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [25]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [16]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [34]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Pentamidine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [16]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [16]
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Pentamidine and Etelcalcetide. Hyper-parathyroidism [5A51] [18]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [20]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Balsalazide. Indeterminate colitis [DD72] [36]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Polyethylene glycol. Irritable bowel syndrome [DD91] [18]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Phenolphthalein. Irritable bowel syndrome [DD91] [16]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Pentamidine and Crizotinib. Lung cancer [2C25] [37]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Pentamidine and Ceritinib. Lung cancer [2C25] [16]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Pentamidine and Osimertinib. Lung cancer [2C25] [38]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Pentamidine and Selpercatinib. Lung cancer [2C25] [18]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Pentamidine and Lumefantrine. Malaria [1F40-1F45] [20]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Pentamidine and Halofantrine. Malaria [1F40-1F45] [39]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Pentamidine and Hydroxychloroquine. Malaria [1F40-1F45] [40]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Primaquine. Malaria [1F40-1F45] [16]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [18]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Pentamidine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [41]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Pentamidine and Vemurafenib. Melanoma [2C30] [16]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and LGX818. Melanoma [2C30] [42]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Pentamidine and Exjade. Mineral absorption/transport disorder [5C64] [43]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Pentamidine and Panobinostat. Multiple myeloma [2A83] [44]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Thalidomide. Multiple myeloma [2A83] [20]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Pentamidine and Siponimod. Multiple sclerosis [8A40] [20]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Pentamidine and Fingolimod. Multiple sclerosis [8A40] [16]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Pentamidine and Ocrelizumab. Multiple sclerosis [8A40] [45]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Pentamidine and Ozanimod. Multiple sclerosis [8A40] [46]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Romidepsin. Mycosis fungoides [2B01] [16]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Pentamidine and Nilotinib. Myeloproliferative neoplasm [2A20] [16]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Dasatinib. Myeloproliferative neoplasm [2A20] [47]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Promethazine. Nausea/vomiting [MD90] [16]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Granisetron. Nausea/vomiting [MD90] [16]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Pentamidine and Dolasetron. Nausea/vomiting [MD90] [16]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Ondansetron. Nausea/vomiting [MD90] [16]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Entrectinib. Non-small cell lung cancer [2C25] [20]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Pentamidine and Levomethadyl Acetate. Opioid use disorder [6C43] [18]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lofexidine. Opioid use disorder [6C43] [16]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Rucaparib. Ovarian cancer [2C73] [16]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Buprenorphine. Pain [MG30-MG3Z] [16]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Triclabendazole. Parasitic worm infestation [1F90] [16]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Pimavanserin. Parkinsonism [8A00] [48]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Famotidine. Peptic ulcer [DA61] [20]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Pentamidine and Macimorelin. Pituitary gland disorder [5A60-5A61] [49]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Pentamidine and Lefamulin. Pneumonia [CA40] [50]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Pentamidine and Ritodrine. Preterm labour/delivery [JB00] [23]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Degarelix. Prostate cancer [2C82] [18]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Pentamidine and ABIRATERONE. Prostate cancer [2C82] [18]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Enzalutamide. Prostate cancer [2C82] [18]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Relugolix. Prostate cancer [2C82] [18]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Bicalutamide. Prostate cancer [2C82] [18]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Levomepromazine. Psychotic disorder [6A20-6A25] [16]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Pentamidine and Everolimus. Renal cell carcinoma [2C90] [51]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Pentamidine and Temsirolimus. Renal cell carcinoma [2C90] [51]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Pentamidine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [52]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Sulfasalazine. Rheumatoid arthritis [FA20] [36]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Quetiapine. Schizophrenia [6A20] [16]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Pentamidine and Mesoridazine. Schizophrenia [6A20] [16]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Aripiprazole. Schizophrenia [6A20] [20]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Pentamidine and Iloperidone. Schizophrenia [6A20] [16]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Paliperidone. Schizophrenia [6A20] [16]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Perphenazine. Schizophrenia [6A20] [16]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Trifluoperazine. Schizophrenia [6A20] [16]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Pentamidine and Amisulpride. Schizophrenia [6A20] [20]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Asenapine. Schizophrenia [6A20] [16]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Pentamidine and Pimozide. Schizophrenia [6A20] [18]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Vardenafil. Sexual dysfunction [HA00-HA01] [16]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Pentamidine and LEE011. Solid tumour/cancer [2A00-2F9Z] [16]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Pentamidine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [16]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [18]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [16]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Pitolisant. Somnolence [MG42] [16]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [16]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Lenvatinib. Thyroid cancer [2D10] [16]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Pentamidine and Cabozantinib. Thyroid cancer [2D10] [18]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Pentamidine and Papaverine. Tonus and reflex abnormality [MB47] [53]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Pentamidine and Sirolimus. Transplant rejection [NE84] [51]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Pentamidine and Tacrolimus. Transplant rejection [NE84] [51]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Olsalazine. Ulcerative colitis [DD71] [36]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Plazomicin. Urinary tract infection [GC08] [20]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [54]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Pentamidine and Procainamide. Ventricular tachyarrhythmia [BC71] [16]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Propafenone. Ventricular tachyarrhythmia [BC71] [16]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Pentamidine and Flecainide. Ventricular tachyarrhythmia [BC71] [16]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Pentamidine and Amiodarone. Ventricular tachyarrhythmia [BC71] [16]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Pentamidine and Ganciclovir. Virus infection [1A24-1D9Z] [20]
Valganciclovir DMS2IUH Moderate Increased risk of nephrotoxicity by the combination of Pentamidine and Valganciclovir. Virus infection [1A24-1D9Z] [20]
⏷ Show the Full List of 152 DDI Information of This Drug

References

1 Pentamidine FDA Label
2 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
8 Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
9 Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
10 Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5.
11 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
12 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
13 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
14 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
15 Bisbenzamidine derivative, pentamidine represses DNA damage response through inhibition of histone H2A acetylation. Mol Cancer. 2010 Feb 9;9:34. doi: 10.1186/1476-4598-9-34.
16 Canadian Pharmacists Association.
17 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
20 Cerner Multum, Inc. "Australian Product Information.".
21 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
22 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
23 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
24 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
25 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
26 Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
27 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
28 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
29 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
30 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
31 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
32 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
33 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
34 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
35 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
36 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
37 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
39 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
40 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
41 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
42 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
43 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
44 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
45 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
46 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
47 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
48 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
49 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
50 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
51 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
52 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
53 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
54 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]